Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key

 
• By Cathy Kelly

Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.

SC1901_Novartis logo_751955164 _1200.jpg
A Closer Look At Novartis' US Market Acess Plan For Inclisiran

More from Market Access

More from Pink Sheet